Compare GSK plc (GSK) vs Skyworks Solutions Inc (SWKS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Skyworks Solutions Inc — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Skyworks Solutions Inc trades at $76.35 (market cap $12.15B). The key difference: GSK plc is far larger — about 7.6× Skyworks Solutions Inc's market cap, and Skyworks Solutions Inc pays the higher dividend (4.13%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Skyworks Solutions Inc for 50 Days on average.
| GSK | SWKS | |
|---|---|---|
Market Cap | $91.88B | $12.15B |
Volume | 7,730,529 | 7,390,810 |
Sector | Health | Technology |
52-Week High | $61.18 | $91.45 |
52-Week Low | $43.24 | $52.50 |
Typical Hold Time | 93 Days | 50 Days |
Enterprise Value | $111.88B | $12.03B |
Dividend Yield | 3.9% | 4.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.36 exceeding the $1.27 estimate. Fundamentals show robust profitability with a 72.73% gross margin and 14.52% net margin, while valuation metrics like a P/E of 14.89 appear reasonable. Recent news highlights pipeline advancements, including a $750 million cancer therapy deal and strategic focus on oncology and cost savings.
The outlook is mixed; analyst consensus leans Hold (55.18%) with a minority Buy rating (31.03%), reflecting caution amid an approaching HIV patent cliff. Near-term support is at $45, with resistance at $47. Revenue growth to $33.2B in 2026 and a dividend of $0.45 per share offer stability, but execution risks and competitive pressures remain key watchpoints for investors.
Skyworks Solutions (SWKS) trades at $80.75, down 3.21% today, with a bearish technical signal despite recent earnings beats. The company shows declining revenue and profit margins over recent years, with 2025 revenue at $4.09B and net income of $477.1M. Key developments include the pending Qorvo merger, which has driven recent volatility and analyst optimism about potential synergies.
The investment outlook is mixed: strong analyst support (60% buy ratings) and merger potential offer upside, but declining fundamentals and bearish technicals present near-term risks. The consensus price target of $78.80 suggests limited upside from current levels, making careful monitoring of merger progress and Q3 earnings crucial.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →
